ProCE Banner Activity

Planned Interim Analysis of Phase II HOVON 143 Study of Ixazomib, Daratumumab, and Low-Dose Dex in Unfit, Frail Patients With Newly Diagnosed Multiple Myeloma

Slideset Download
Conference Coverage
Preliminary assessment found treatment was tolerable with promising ORR in this hard-to-treat MM population

Released: December 10, 2018

Expiration: December 09, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology